Onfekafusp alfa not checked
Philogen S.p.A. · L19TNF · L19TNF and CCNU
FollowEvery change as it happens, and a Monday email
Trials
6 active
13 in total · 7 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day”In the company’s words, NCT04733183 on ClinicalTrials.gov
- Tested for
- Glioblastoma (2 trials), Soft Tissue Sarcoma, Melanoma Stage III, Melanoma Stage IV, Glioma, Locally Advanced Basal Cell Carcinoma
- Main trialPhase 2
- “Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.”In the company’s words, NCT04733183 on ClinicalTrials.gov
- Other names
- L19TNF · onfekafusp alpha · L19TNF and CCNU · L19TNF and CCNU in recurrent astrocytoma · L19TNF and TMZ · L19TNF and TMZ in recurrent astrocytoma
Other drugs for Glioblastoma
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- LAM561Laminar Pharmaceuticals · Phase 2/3
- VebreltinibBeijing Pearl Biotechnology Limited Liability Company · Phase 2/3
Coming up3
- Jul 2028Phase 2 trial completes · ClinicalTrials.gov
- 30 Jan 2029Phase 2 trial completes · ClinicalTrials.gov
- Feb 2031Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Dec 2025 | Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma | |
| Phase 2Active, not recruiting | Jun 2026 | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence | |
| Phase 2Recruiting | Jul 2028 | Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients | |
| Phase 2Not yet recruiting | 30 Jan 2029 | A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma | |
| Phase 2Recruiting | Feb 2031 | L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) | |
| Phase 1/2Recruiting | Oct 2026 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma | |
| Phase 3Unknown | 31 Dec 2025 | A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma | |
| Phase 2Unknown | Dec 2024 | Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA) | |
| Phase 1/2Completed | 27 Jun 2023 | Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse | |
| Phase 1/2Unknown | Mar 2025 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression | |
| Phase 1Completed | 25 Jan 2018 | L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours | |
| Phase 1Unknown | Dec 2024 | Dose Finding Study of L19TNF and Doxorubicin in Patients With STS | |
| Phase 1Withdrawn | 31 Dec 2024 | Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026